Visualize Lesion-level Plaque Composition
Elucid (elucid.com) earns a Brand Analyzer score of 74 out of 100, placing it in the Brand-Ready tier among Healthcare brands, SaaS brands. Among 2305 Healthcare brands analyzed, Elucid ranks in the 83rd percentile (category average 68, leader 95). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 100/100, Digital Presence 82/100, Visual Identity 90/100, Messaging Clarity 95/100, Trust Foundation 62/100, AI Discoverability 39/100, Brand Authority 59/100.
Elucid is a healthcare technology company that develops AI-powered software for coronary plaque assessment. Its flagship product, PlaqueIQ, uses CT angiography (CTA) data trained on gold-standard histology to quantify plaque composition and vessel structure. The tool is designed to help physicians identify vulnerable plaques that traditional diagnostics may miss, with the stated potential to prevent 80-90% of heart attacks. Elucid operates in the Healthcare and SaaS categories.
| Brand Name | Elucid |
|---|---|
| Domain | elucid.com |
| Industry | Healthcare, SaaS |
| Main Competitors | HeartFlow, Cleerly (69/100), Siemens Healthineers, Philips Healthcare, Nanox (Zebra Medical Vision), Viz.ai |
Moz Domain Authority 57/100 vs category average 29 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Elucid has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Elucid develops AI-powered plaque assessment to identify preventable heart risks using CT angiography and ground-truth histology." (No meta description) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on YouTube, Facebook, Instagram, GitHub; no detected presence on LinkedIn, X (Twitter) - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Elucid scores 52/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Elucid has a limited AI-visibility profile at 52/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (66/100) and its weakest is trust (39/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a Moz Domain Authority of 57/100. The main gaps holding it back: thin schema.org structured data.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Elucid offers PlaqueIQ, an AI-powered software platform for coronary plaque assessment. PlaqueIQ uses CT angiography data and is trained on gold-standard histology to provide precise quantification of plaque composition and vessel structure. It is delivered as a SaaS solution targeting cardiologists and healthcare providers. The product is designed to detect vulnerable plaques and support cardiovascular risk stratification in clinical settings.
Sources: Elucid official site
Elucid's main competitors include HeartFlow, Cleerly (69/100), Siemens Healthineers, Philips Healthcare, Nanox (Zebra Medical Vision). These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Elucid official site
Elucid and Cleerly are competitors in Healthcare. Brand Analyzer scores Elucid at 74/100 and Cleerly at 69/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Elucid official site
Elucid is a healthcare technology company that develops AI-powered software for cardiovascular risk assessment. It operates in the Healthcare and SaaS sectors and focuses on coronary plaque analysis. Its platform is designed to give physicians precise, quantitative data about plaque composition and vessel structure using CT angiography, with the goal of identifying preventable heart risks before they result in serious cardiac events.
Sources: Elucid official site
Elucid develops AI-powered plaque assessment tools that analyze CT angiography (CTA) data to identify and quantify coronary plaque composition and vessel structure. Its technology is trained on gold-standard histology data, allowing it to detect vulnerable plaques that traditional diagnostics may miss. The company states its approach has the potential to prevent 80-90% of heart attacks by enabling earlier and more precise cardiovascular risk assessment by physicians.
Sources: Elucid official site
Popular alternatives to Elucid include HeartFlow, Cleerly (69/100), Siemens Healthineers, Philips Healthcare, Nanox (Zebra Medical Vision). Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Elucid official site
Elucid has moderate AI-search visibility, scoring 52/100 on Brand Analyzer's AI visibility composite (visibility 53, trust 39, recommendation 66). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Elucid official site
Elucid is known for its PlaqueIQ product, which is described as the only CTA-based tool trained on gold-standard histology for precise quantification of plaque composition and vessel structure. The company is recognized for applying AI to coronary plaque analysis in a way that is validated against histological ground truth, distinguishing it from conventional diagnostic tools in cardiovascular medicine.
Sources: Elucid official site
Elucid's products are designed for cardiologists, physicians, and healthcare providers who manage patients at risk of atherosclerosis and cardiovascular disease. The platform is intended for clinical use in settings where precise coronary plaque assessment and cardiovascular risk stratification are needed, supporting medical decision-making for patients who may be at risk of heart attacks or other serious cardiac events.
Sources: Elucid official site
Elucid scores 66/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Elucid official site
Elucid can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Elucid official site
Based on available facts, Elucid's appeal stems from offering a differentiated approach to cardiovascular risk assessment. PlaqueIQ is positioned as the only CTA-based plaque analysis tool trained on gold-standard histology, enabling detection of vulnerable plaques missed by traditional diagnostics. The potential to prevent 80-90% of heart attacks is a significant clinical value proposition that may drive interest among cardiologists and healthcare providers focused on preventive cardiology.
Sources: Elucid official site
Ranked closest to Elucid: Docuvera (74/100), Doctors Without Borders (MSF) (74/100), Empxtrack (74/100), Envision (74/100).
A step up - brands to learn from: Zipline (81/100), Zimmer Biomet (81/100).
Category leader: Dassault Systèmes (95/100).